StockData
Palvella Therapeutics, Inc. logo

Palvella Therapeutics, Inc. (PVLA) stock

PVLANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$142.85−2.92 (-2.00%)

Close on Nov 20, 2026Market cap $2.06BP/E –Yield –

Palvella Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Palvella Therapeutics's free cash flow for the twelve months ending Sep 30, 2024 was $15.01M. For fiscal 2023 it was -$13.87M. The highest annual figure on record is $47.80M in fiscal 2017.

Annual free cash flow

PeriodPeriod endValueChange
FY2023Dec 31, 2023-$13.87M–
FY2022Dec 31, 2022-$60.97M–
FY2021Dec 31, 2021-$8.61M–
FY2020Dec 31, 2020-$48.62M–
FY2019Dec 31, 2019-$54.93M–
FY2018Dec 31, 2018-$2.76M-105.8%
FY2017Dec 31, 2017$47.80M–
FY2016Dec 31, 2016-$14.95M–
FY2015Dec 31, 2015-$13.33M–
FY2014Dec 31, 2014-$5.33M–
FY2013Dec 31, 2013-$3.13M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2024Sep 30, 2024-$2.74M–
Q2 FY2024Jun 30, 2024-$1.60M–
Q1 FY2024Mar 31, 2024-$1.10M–
Q4 FY2023Dec 31, 2023$20.46M–
Q3 FY2023Sep 30, 2023-$9.79M–
Q2 FY2023Jun 30, 2023-$13.50M–
Q1 FY2023Mar 31, 2023-$11.04M–
Q4 FY2022Dec 31, 2022-$12.92M–
Q3 FY2022Sep 30, 2022-$8.81M–
Q2 FY2022Jun 30, 2022-$16.21M-154.6%
Q1 FY2022Mar 31, 2022-$23.03M–
Q4 FY2021Dec 31, 2021-$11.29M–
Q3 FY2021Sep 30, 2021-$14.83M–
Q2 FY2021Jun 30, 2021$29.68M–
Q1 FY2021Mar 31, 2021-$12.17M–
Q4 FY2020Dec 31, 2020-$14.00M–
Q3 FY2020Sep 30, 2020-$6.73M–
Q2 FY2020Jun 30, 2020-$10.84M–
Q1 FY2020Mar 31, 2020-$17.06M–
Q4 FY2019Dec 31, 2019-$15.15M–
Q3 FY2019Sep 30, 2019-$12.88M–
Q2 FY2019Jun 30, 2019-$11.67M–
Q1 FY2019Mar 31, 2019-$15.23M-149.2%
Q4 FY2018Dec 31, 2018-$9.62M–
Q3 FY2018Sep 30, 2018-$14.68M-142.1%
Q2 FY2018Jun 30, 2018-$9.38M–
Q1 FY2018Mar 31, 2018$30.93M+20.8%
Q4 FY2017Dec 31, 2017-$5.51M–
Q3 FY2017Sep 30, 2017$34.91M–
Q2 FY2017Jun 30, 2017-$7.19M–
Q1 FY2017Mar 31, 2017$25.59M–
Q4 FY2016Dec 31, 2016-$6.97M–
Q3 FY2016Sep 30, 2016-$3.77M–

More Palvella Therapeutics figures

See a number that looks wrong?